Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
8
×
boston top stories
fda
cancer
clinical trials
startups
abbvie
amgen
cancer immunotherapy
europe blog main
europe top stories
gilead sciences
ipo
medical devices
What
roundup
bio
new
acquisitions
biotech
ceo
covid
daniel
days
drug
drugs
fda
gilead
including
ipo
medicines
news
o’day
sciences
abbvie’s
according
activity
advantages
ahead
akcea
announced
approvals
august
bails
bar
biggest
biofourmis
biogen
brand
bridgebio
brings
bucks
build
busy
buy
Language
unset
8
×
Current search:
biotech
×
novartis
×
" wisconsin top stories "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More